Pharscin Pharma(SZ:002907) Shang Hai Zheng Quan Bao·2025-12-30 23:45Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received approval for a change in its production license for special medical purpose formula foods, expanding its product range [1][4]. Group 1: License Change - The company has obtained a new production license for special medical purpose formula foods, which includes an expanded range of food categories [1]. - The updated license is issued by the Chongqing Municipal Market Supervision Administration [1]. Group 2: Product Information - The company's Gan Yimei liquid formula food is designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders, featuring a scientific formula with 0 fat and 0 fiber [2]. - The product provides a high carbohydrate energy ratio of 87%, ensuring quick energy supply with minimal digestive burden, and includes essential vitamins and minerals for balanced nutrition [2]. - It is suitable for nutritional support in conditions such as acute pancreatitis and short bowel syndrome, and can also be used as a standardized liquid diet before colonoscopy [2]. Group 3: Market Potential - The global market for special medical purpose formula foods is estimated to reach $24.8 billion in 2024, with a projected compound annual growth rate (CAGR) of 5.13%, reaching $33.49 billion by 2030 [2]. - In China, the market size for special medical purpose formula foods is estimated at RMB 16.4 billion (approximately $2.27 billion) in 2024, holding the largest revenue share in the Asia-Pacific region, accounting for 9.15% of the global market [2]. - The Chinese market is expected to grow at a CAGR of 6.58%, reaching RMB 24 billion (approximately $3.33 billion) by 2030, indicating significant potential due to low current clinical usage rates compared to developed countries [2].